Skip to content
Search

Latest Stories

NHS digital shift: Majority willing to share health data, but hesitant about care robots

Three-quarters of the public open to sharing their health data to develop AI in the NHS – survey finds
Young woman using running app on smart watch and smartphone to track pace and time. gettyimages

Three-quarters of the public open to sharing some of their health data to develop AI in the NHS – survey finds 

Transitioning from analogue to digital is one of three major "shifts" the government has deemed essential for the future of the NHS. These shifts, with the other two being the moving from hospital to community care and from sickness to prevention, will also form the foundation of the 10-Year Health Plan.

The question is: are the public ready to embrace this digital transformation, which would involve sharing their health data for the development of artificial intelligence (AI) systems within the NHS?


Results from a UK-wide poll show that the majority of people (75 per cent) are willing to share some of their health data for AI development.

The survey commissioned by the Health Foundation included more than 7,000 members of the public (aged 16 years and older).

Nearly 60 per cent expressed willingness to share information about their eye health, with 58 per cent open to sharing details about the medications they are taking, and 57 per cent willing to disclose any long-term illnesses they live with.

However, the results found less willingness to share certain types of data, with only 47 per cent open to sharing smartphone-tracked data, such as sleep activity, and 44 per cent willing to share sexual health information—fewer than the 46 per cent who opposed sharing this data.

Dr Malte Gerhold, director of innovation and improvement at the Health Foundation, emphasized that the government can only successfully achieve its ambition of shifting the NHS from analogue to digital with the public’s support.

“It is encouraging that most people are open to sharing their data to develop AI systems in the NHS,” he said.

Dr Gerhold noted that when properly implemented, AI has the potential to “free up staff by supporting clinical and administrative tasks.”

"However, these systems are only as good as the data used to design and develop them."

The polling also uncovered significant differences between socioeconomic groups in levels of support for sharing data for AI development and for taking part in activities to shape how technology is used in the NHS.

In particular, individuals from socioeconomic groups D and E (where the primary earner is semi-skilled, unskilled, or unemployed) were much less likely to support the use of their health data compared to those from other socioeconomic groups.

Dr Gerhold urged policymakers, NHS leaders, and those involved in designing and implementing health care technologies to “proactively engage with people across different social groups to ensure that health care technologies help tackle inequalities, rather than worsen them.”

The survey also found that the public is hesitant about technologies, like care robots, that might be seen to ‘distance’ patients from healthcare staff or come between them.

People cited the ability to see and talk to NHS staff as their most important consideration when thinking about technology use in health care, with older people particularly concerned about this

Public trust in the NHS holding personal health data is strong, with around two-thirds of the respondents expressing either high or moderate levels of trust in the NHS managing their health information.

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less